...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis
【24h】

Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis

机译：在两种不同的皮肤利什曼病鼠模型中评估利什曼原虫主要重组核糖体蛋白L3或L5的免疫应答和疫苗接种效果的分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Four new antigenic proteins located in Leishmania ribosomes have been characterized: S4, S6, L3 and L5. Recombinant versions of the four ribosomal proteins from Leishmania major were recognized by sera from human and canine patients suffering different clinical forms of leishmaniasis. The prophylactic properties of these proteins were first studied in the experimental model of cutaneous leishmaniasis caused by L. major inoculation into BALB/c mice. The administration of two of them, LmL3 or LmL5 combined with CpG-oligodeoxynucleotides (CpG-ODN) was able to protect BALB/c mice against L. major infection. Vaccinated mice showed smaller lesions and parasite burden compared to mice inoculated with vaccine diluent or vaccine adjuvant. Protection was correlated with an antigen-specific increased production of IFN-gamma paralleled by a decrease of the antigen-specific IL-10 mediated response in protected mice relative to non-protected controls. Further, it was demonstrated that BALB/c mice vaccinated with recombinant LmL3 or LmL5 plus CpG-ODN were also protected against the development of cutaneous lesions following inoculation of L. braziliensis. Together, data presented here indicate that LmL3 or LmL5 ribosomal proteins combined with Th1 inducing adjuvants, may be relevant components of a vaccine against cutaneous leishmaniasis caused by distinct species
机译：位于利什曼原虫核糖体中的四个新抗原蛋白已被表征：S4，S6，L3和L5。来自利什曼原虫的四种核糖体蛋白的重组形式被患有不同临床形式利什曼病的人和犬患者的血清识别。这些蛋白的预防特性首先在由BA.L / c小鼠中接种大麦芽孢杆菌引起的皮肤利什曼病的实验模型中进行了研究。将LmL3或LmL5中的两个与CpG-寡脱氧核苷酸（CpG-ODN）组合使用，可以保护BALB / c小鼠免受大肠埃希氏菌感染。与接种疫苗稀释剂或疫苗佐剂的小鼠相比，接种疫苗的小鼠显示出较小的病变和寄生虫负担。保护与IFN-γ的抗原特异性产生增加相关，同时与相对于未保护的对照，受保护的小鼠中抗原特异性IL-10介导的应答的降低相平行。此外，已证明用重组LmL3或LmL5加CpG-ODN疫苗接种的BALB / c小鼠也被保护免于接种巴西乳杆菌后皮肤损伤的发展。总之，此处提供的数据表明，LmL3或LmL5核糖体蛋白与Th1诱导佐剂相结合，可能是针对由不同物种引起的皮肤利什曼病的疫苗的相关成分

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号